Abstract
TACI is a member of the tumor necrosis factor receptor superfamily and serves as a key regulator of B cell function. The extracellular domain of a typical TNFR contains multiple copies of CRD, which bind in the monomermonomer interfaces of a trimeric ligand. TACI binds to two ligands, APRIL and BAFF, with high affinity and contains two CRD in its extracellular regions, while BCMA and BR3, contain a single or partial CRD for binding the two ligands. However, TACI can be classified as a single CRD receptor because the amino-terminal CRD1 doesnt contribute to ligand binding. To obtain a new variant of TACI possessing higher affinities for binding, we fused a repeat sequence of CRD2 to the N-terminus of the short form of TACI. The new APRIL antagonist peptide, CRD2-shortTACI-Fc, was designed based on the modeling 3-D complex structure of TACI and APRIL. As expected, the purified recombinant CRD2-shortTACI-Fc fusion protein could bind to APRIL in vitro and demonstrated dose-dependent inhibition of APRIL-induced proliferative activity in Raji cells. We found that CRD2-shortTACI-Fc, has a higher affinity for binding to ligands than short-TACI-Fc, which contains a single CRD2.
Keywords: TACI, CRD2, BAFF, APRIL, affinity, autoimmune disorders, Novagen, DNA ligase, homology modeling, Pichia pastoris
Protein & Peptide Letters
Title: Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris
Volume: 19 Issue: 3
Author(s): Rui Wang, Shiliang Zhou, Xiaomin Peng, Xin-Wen Zhou, Zhi-Qun Xie, Yuxiong Wang, Wei Mo and Min Yu
Affiliation:
Keywords: TACI, CRD2, BAFF, APRIL, affinity, autoimmune disorders, Novagen, DNA ligase, homology modeling, Pichia pastoris
Abstract: TACI is a member of the tumor necrosis factor receptor superfamily and serves as a key regulator of B cell function. The extracellular domain of a typical TNFR contains multiple copies of CRD, which bind in the monomermonomer interfaces of a trimeric ligand. TACI binds to two ligands, APRIL and BAFF, with high affinity and contains two CRD in its extracellular regions, while BCMA and BR3, contain a single or partial CRD for binding the two ligands. However, TACI can be classified as a single CRD receptor because the amino-terminal CRD1 doesnt contribute to ligand binding. To obtain a new variant of TACI possessing higher affinities for binding, we fused a repeat sequence of CRD2 to the N-terminus of the short form of TACI. The new APRIL antagonist peptide, CRD2-shortTACI-Fc, was designed based on the modeling 3-D complex structure of TACI and APRIL. As expected, the purified recombinant CRD2-shortTACI-Fc fusion protein could bind to APRIL in vitro and demonstrated dose-dependent inhibition of APRIL-induced proliferative activity in Raji cells. We found that CRD2-shortTACI-Fc, has a higher affinity for binding to ligands than short-TACI-Fc, which contains a single CRD2.
Export Options
About this article
Cite this article as:
Wang Rui, Zhou Shiliang, Peng Xiaomin, Zhou Xin-Wen, Xie Zhi-Qun, Wang Yuxiong, Mo Wei and Yu Min, Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris, Protein & Peptide Letters 2012; 19 (3) . https://dx.doi.org/10.2174/092986612799363136
DOI https://dx.doi.org/10.2174/092986612799363136 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenomics of Human ABC Transporters: Detection of Clinically Important SNPs by SmartAmp2 Method
Current Pharmaceutical Biotechnology A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
Anti-Cancer Agents in Medicinal Chemistry Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1
Current Gene Therapy Structure, Substrate Complexation and Reaction Mechanism of Bacterial Asparaginases
Current Chemical Biology Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Molecular Mechanism of Deguelin in Anti-tumor Effect
Current Pharmaceutical Analysis Resveratrol and Prostate Cancer: The Power of Phytochemicals
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Stem Cell Research & Therapy Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Retinoids in Clinical Use
Medicinal Chemistry Prospective Observation for Seven-Year's Highly Active Antiretroviral Therapy in Chinese HIV-1 Infected Patients
Current HIV Research Identification of Marker Genes for Cancer Based on Microarrays Using a Computational Biology Approach
Current Bioinformatics Discovery of Novel HDAC Inhibitors by Structure-based Optimization of Cinnamic Hydroxamic Scaffold
Letters in Drug Design & Discovery Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme
Current Pharmaceutical Design Evaluation of Drug Targeting Strategies and Liposomal Trafficking
Current Pharmaceutical Design